Osimertinib was developed for its activity against T790M by covalently binding to T790M-muted EGFR10, and it has been shown to be effective against AR of T790M-positive NSCLC after 1st- or 2nd-G EGFR-TKI treatment11. This evidence concerns the gene EGFR and non-small cell lung carcinoma.